Molecular targeting of the PKC‐β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin‐treated KMS‐26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B‐cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin‐treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM. Copyright © 2008 John Wiley & Sons, Ltd.

[1]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[2]  S. Sacchi,et al.  The oral protein-kinase C β inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines , 2008, Leukemia & lymphoma.

[3]  Damon L. Meyer,et al.  Antibody targeting of B-cell maturation antigen on malignant plasma cells , 2007, Molecular Cancer Therapeutics.

[4]  N. Munshi,et al.  Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). , 2006, Blood.

[5]  C. Mackay,et al.  Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. , 2006, Pharmacology & therapeutics.

[6]  Roger Sciammas,et al.  Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. , 2006, Immunity.

[7]  F. Weinberg,et al.  Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines , 2006, Molecular Cancer Therapeutics.

[8]  N. Munshi,et al.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.

[9]  Qiong Shen,et al.  Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination , 2006, Nature Immunology.

[10]  S. Dillon,et al.  An APRIL to remember: novel TNF ligands as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[11]  S. Bicciato,et al.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Campbell,et al.  The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .

[13]  S. Bicciato,et al.  Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma , 2005, Oncogene.

[14]  K. Tarte,et al.  BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone , 2003 .

[15]  John Calvin Reed,et al.  The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.

[16]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[17]  K. Kataoka,et al.  MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun , 1994, Molecular and cellular biology.